Quanterix Corp
quanterix.comQuanterix Corp (NASDAQ: QTRX) is a life sciences tools company that develops and sells instruments, assays, and software for ultrasensitive biomarker detection and spatial biology analysis. Revenue comes from instrument sales, consumable assay kits, software licenses, and service contracts tied to platforms including Simoa HD-X, Simoa ONE, SR-X, SP-X, PhenoCycler, PhenoImager Fusion, and PhenoImager HT. The company acquired Akoya Biosciences in 2024, adding spatial biology instrument lines, and acquired Emission in January 2025, a manufacturer of dye-encapsulating magnetic beads based in Georgetown, Texas, to secure bead supply for next-generation platforms and expand into a multi-plex segment targeting third-party original equipment manufacturer customers. Quanterix serves academic researchers, pharmaceutical and biopharmaceutical companies, and clinical laboratory customers. FY2025 results were pressured by reduced U.S. federal research funding, lower pharmaceutical customer R&D spending, and new import tariffs, which drove a goodwill impairment charge of $6.4 million and restructuring actions targeting approximately $85.0 million in annualized operating expense reductions.
Products & Services
Simoa HD-X, Simoa ONE, SR-X, SP-X (single-molecule array ultrasensitive detection instruments); PhenoCycler, PhenoImager Fusion, PhenoImager HT (spatial biology imaging platforms); PhenoCode barcoded antibody assays; QPTIFF proprietary image format and image analysis software; LucentAD and Lucent Diagnostics neurological laboratory-developed tests; Emission magnetic bead products for low- and mid-plex assays.
Revenue Model
Instrument sales (capital equipment), recurring consumable assay revenue, software licenses, and service contracts. The Simoa and spatial biology platform lines generate instrument placements followed by consumable pull-through. Emission adds a bead manufacturing capability intended to supply internal platforms and third-party OEM customers.
Customers & Markets
Academic and government research institutions, pharmaceutical and biopharmaceutical companies (including large pharma R&D groups), clinical laboratories, and translational research organizations. End markets include neurology biomarker research, oncology translational research, biomarker validation, and spatial proteomics. FY2025 revenue was materially affected by reductions in U.S. federal research funding and reduced R&D spending by larger pharmaceutical customers.
Geographic Exposure
Primary operations in the United States. Emission manufacturing based in Georgetown, Texas. International sales implied by regulatory disclosures covering GDPR and other non-U.S. data privacy regimes, but specific geographic revenue splits are not detailed in the excerpts provided.
Financial Snapshot
Loading...
